In short
Clinical trials are investigating AZD1163 in adults with moderately to severely active rheumatoid arthritis. The main goal is to check whether it can improve symptoms and inflammation, and to assess safety and clinical efficacy compared with placebo.
Key points
- Clinical trials are studying AZD1163 in adults with moderately to severely active rheumatoid arthritis. The available trial is a Phase 2 interventional study with 295 planned participants. It compares AZD1163 with placebo to evaluate clinical efficacy and safety. The main outcome is the change in DAS28-CRP at Week 12, which measures disease activity. The trial is authorised and focuses on whether AZD1163 can improve symptoms and inflammation in this patient group.
Trial overview
The available study is an interventional study, which means researchers give a study treatment and then measure the results. It is investigating AZD1163 in adults with rheumatoid arthritis that is moderately to severely active. The trial is Phase 2 and has a planned enrollment of 295 participants.
Who can participate
This study is designed for adult participants with rheumatoid arthritis. The title says the condition must be moderately to severely active, which means the disease is causing a meaningful level of symptoms and inflammation. The trial data do not list more detailed entry rules, so the exact participation criteria are not provided here.
Study design and treatment groups
The study compares AZD1163 with placebo, which is a look-alike treatment used for comparison. The intervention is listed as AZD1163 given by subcutaneous use, meaning it is administered as an injection under the skin. The brief summary says the goal is to evaluate the clinical efficacy of AZD1163 compared with placebo.
What the study measures
The main endpoint is the change from baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12. Baseline means the starting point before treatment begins. DAS28-CRP is a score used to show how active rheumatoid arthritis is, so changes in this score help show whether the study treatment is helping.
What the results may mean
This trial is focused on whether AZD1163 can improve symptoms and inflammation in people with active rheumatoid arthritis. Because it is a Phase 2 study, the results may help researchers learn more about both benefit and safety before larger studies are done. The study status is listed as Authorised, which means it has been approved to move forward in the trial process.